Agenus | AGEN - Net Income


Agenus reported $39.17M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Agenus USD 39.17M 49.8M Mar/2026
Amgen USD 2.38B 556M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Celldex Therapeutics USD -73.5M 5.18M Jun/2026
CSL USD 401M 96.5M Dec/2025
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
Incyte USD 585.6M 282.27M Jun/2026
J&J USD 210M 5.32B Sep/2026
Jiangsu Hengrui CNY 2.18B 99.1M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Merck EUR 490M 169M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Northwest Biotherapeutics USD -3.4M 23.78M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -248M 2.94B Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Veracyte USD 25.49M 3.22M Jun/2026